<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Fucosylation is a crucial <z:chebi fb="2" ids="50699">oligosaccharide</z:chebi> modification in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Total cellular proteins of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and the sera of patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> both show increased fucosylation levels </plain></SENT>
<SENT sid="2" pm="."><plain>Certain kinds of fucosylated proteins can be applied as novel <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> biomarkers in glyco-proteomic analyses </plain></SENT>
<SENT sid="3" pm="."><plain>We previously identified fucosylated haptoglobin (Fuc-Hpt) as a serologic marker for <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo>, and recently developed a lectin-antibody enzyme-linked immunosorbent assay system for quantifying Fuc-Hpt </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study, we investigated the clinical outcome of Fuc-Hpt levels in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and examined the mechanisms underlying Fut-Hpt production using a murine <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> transplantation model </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: The relationship between Fuc-Hpt levels and clinical parameters was investigated in 77 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, <z:hpo ids='HP_0000001'>all</z:hpo> of whom underwent primary resection </plain></SENT>
<SENT sid="6" pm="."><plain>Serum Fuc-Hpt levels were examined in athymic <z:mp ids='MP_0003815'>nude</z:mp> mice injected with <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines that lacked fucosylation </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Fuc-Hpt levels were significantly associated with overall and relapse-free survival, distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, clinical stage, and curability </plain></SENT>
<SENT sid="8" pm="."><plain>Multivariate analysis revealed that distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> was an independent factor for increased Fuc-Hpt levels </plain></SENT>
<SENT sid="9" pm="."><plain>The combination of Fuc-Hpt and CEA might be a better serologic marker to predict prognosis </plain></SENT>
<SENT sid="10" pm="."><plain>Fuc-Hpt levels were higher in mice with direct injection of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells into the spleen than in those injected subcutaneously </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Fuc-Hpt might be a useful marker for the prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Fuc-Hpt could be produced by the tissue surrounding <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, which might be the mechanism underlying Fuc-Hpt elevation associated with distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
</text></document>